The TAXUS Element (ION) platinum chromium paclitaxel-eluting stent (PES) incorporates a novel thin-strut design to increase radiopacity and deliverability compared to prior TAXUS stents. Although the ION stent was non-inferior to the TAXUS Express PES in workhorse lesions and superior to the bare metal Express stent in small vessel lesions at 1 year in the PERSEUS studies, longer term outcomes have not been reported. Methods: PERSEUS Workhorse (WH) is a prospective, Bayesian, 3:1 randomized (ION versus TAXUS Express; Boston Scientific) trial in subjects with lesion length ≤28mm and vessel diameter ≥2.75 to ≤4.0mm which demonstrated non-inferiority for the 12-month primary TLF endpoint. PERSEUS Small Vessel (SV) is a prospective, single-arm trial in subjects with lesion length ≤20mm and vessel diameter ≥2.25 to <2.75mm comparing ION to a matched historical BMS Express control (TAXUS V) which demonstrated superiority for the 9-month primary endpoint (angiographic instent late loss). Results: Clinical events to 2 years are shown (Table) . No differences in safety/efficacy measures were observed between stents in PERSEUS WH. Late revascularization rates were reduced by ION in PERSEUS SV.
